Trevi Therapeutics announces positive results for Haduvio in Phase 2b CORAL study
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, has reported a positive outcome from the planned sample size re-estimation (SSRE) for its ongoing Phase 2b trial. ... Read More
Trevi Therapeutics reports promising results for Oral Nalbuphine in human abuse potential study
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced positive oral nalbuphine results from its human abuse potential (HAP) study evaluating the investigational therapy Haduvio™ for ... Read More
Tvardi Therapeutics initiates REVERTIPF trial in idiopathic pulmonary fibrosis
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in the development of STAT3 inhibitors, has reached a significant milestone by dosing the first patients in ... Read More
BMS-986278 succeeds in phase 2 idiopathic pulmonary fibrosis trial, says Bristol Myers Squibb
Bristol Myers Squibb (BMS) said that BMS-986278 has succeeded in lowering the rate of lung function decline in idiopathic pulmonary fibrosis patients in a phase ... Read More
Clinical-stage Redx Pharma, Jounce Therapeutics sign $425m merger deal
Redx Pharma, a UK-based clinical-stage biotechnology company, and Jounce Therapeutics, a Nasdaq-listed clinical-stage immunotherapy company, have agreed to merge in an all-stock deal that values ... Read More
GRI Bio, Vallon Pharmaceuticals to merge for advancing NKT cell regulators
GRI Bio, a privately held clinical stage biotech company, will merge with a wholly-owned subsidiary of Nasdaq-listed Vallon Pharmaceuticals in an all-stock transaction. The combined ... Read More
AbbVie acquires UK biotech company DJS Antibodies for $255m
AbbVie has acquired DJS Antibodies, a privately-held UK-based biotech company, in an all-cash transaction valued at approximately $255 million, in a move to further strengthen ... Read More
Redx Pharma gets $9m as AstraZeneca initiates AZD5055 phase 1 trial
UK-based biotech company Redx Pharma said that it has received a milestone payment of $9 million from AstraZeneca following the initiation of a phase 1 ... Read More
Glenmark Pharmaceuticals gets FDA approval for Nintedanib Capsules
Glenmark Pharmaceuticals Ltd said that it has secured tentative approval from the US Food and Drug Administration (FDA) for Nintedanib Capsules, 100mg, and 150mg. Nintedanib ... Read More
Galecto raises $64m to develop fibrosis and cancer treatments
Galecto, a Danish biotech company, has raised $64 million in an equity financing round, for developing novel treatments for fibrosis and cancer. Led by Soleus ... Read More